NCT07216794

Small Trial of Alendronate Impact on the Reservoir of HIV

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · NIH
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.

Conditions

• HIV

Interventions

Type	Name	Description
DRUG	Alendronate	70 mg oral capsules
OTHER	Placebo	Matching ALN placebo oral capsules

Timeline

• Start date: 2026-06-27
• Primary completion: 2027-03-26
• Completion: 2027-05-21
• First posted: 2025-10-15
• Last updated: 2026-04-07

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study